Published in Nanomedicine (Lond) on August 14, 2012
Salicylic acid and analogues as diaCEST MRI contrast agents with highly shifted exchangeable proton frequencies. Angew Chem Int Ed Engl (2013) 1.01
Detection of in vivo enzyme activity with CatalyCEST MRI. Magn Reson Med (2014) 1.00
Molecular Imaging of Tumors Using a Quantitative T 1 Mapping Technique via Magnetic Resonance Imaging. Diagnostics (Basel) (2015) 0.83
Dendrimer-Based Responsive MRI Contrast Agents (G1-G4) for Biosensor Imaging of Redundant Deviation in Shifts (BIRDS). Bioconjug Chem (2015) 0.81
Interrogating Metabolism in Brain Cancer. Magn Reson Imaging Clin N Am (2016) 0.79
The effect of regioisomerism on the coordination chemistry and CEST properties of lanthanide(III) NB-DOTA-tetraamide chelates. J Biol Inorg Chem (2013) 0.77
Targeting Glioma with a Dual Mode Optical and Paramagnetic Nanoprobe across the Blood-brain Tumor Barrier. J Nanomed Nanotechnol (2016) 0.77
Targeted Theranostic Approach for Glioma Using Dendrimer-Based Curcumin Nanoparticle. J Nanomed Nanotechnol (2016) 0.76
Oxidation-Responsive, Eu(II/III)-Based, Multimodal Contrast Agent for Magnetic Resonance and Photoacoustic Imaging. ACS Omega (2017) 0.75
Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle. J Nanomed Nanotechnol (2016) 0.75
Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. Nano Lett (2016) 0.75
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson (2000) 8.73
PARACEST agents: modulating MRI contrast via water proton exchange. Acc Chem Res (2003) 4.44
Paramagnetic lanthanide(III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications. Magn Reson Med (2002) 4.03
Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol Imaging (2010) 3.88
Bright ideas for chemical biology. ACS Chem Biol (2008) 3.84
A novel europium(III)-based MRI contrast agent. J Am Chem Soc (2001) 3.71
A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc (2006) 2.26
Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies. Acc Chem Res (2009) 1.95
Design and characterization of a new irreversible responsive PARACEST MRI contrast agent that detects nitric oxide. Magn Reson Med (2007) 1.88
Four-pool modeling of proton exchange processes in biological systems in the presence of MRI-paramagnetic chemical exchange saturation transfer (PARACEST) agents. Magn Reson Med (2008) 1.85
PARACEST MRI with improved temporal resolution. Magn Reson Med (2009) 1.69
Detection of enzymatic activity by PARACEST MRI: a general approach to target a large variety of enzymes. Angew Chem Int Ed Engl (2008) 1.58
MRI detection of paramagnetic chemical exchange effects in mice kidneys in vivo. Magn Reson Med (2007) 1.57
Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med (2008) 1.54
Dendritic PARACEST contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging (2007) 1.50
Polymeric PARACEST agents for enhancing MRI contrast sensitivity. J Am Chem Soc (2008) 1.40
Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Mol Pharm (2009) 1.35
Imaging in vivo extracellular pH with a single paramagnetic chemical exchange saturation transfer magnetic resonance imaging contrast agent. Mol Imaging (2012) 1.34
Measuring in vivo tumor pHe with CEST-FISP MRI. Magn Reson Med (2011) 1.33
Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One (2010) 1.24
Central nervous system germ cell tumors: classification, clinical features, and treatment with a historical overview. J Child Neurol (2009) 1.15
In vivo MRI multicontrast kinetic analysis of the uptake and intracellular trafficking of paramagnetically labeled liposomes. J Control Release (2010) 1.07
Brain temperature and pH measured by (1)H chemical shift imaging of a thulium agent. NMR Biomed (2009) 1.04
Brain temperature by Biosensor Imaging of Redundant Deviation in Shifts (BIRDS): comparison between TmDOTP5- and TmDOTMA-. NMR Biomed (2010) 1.01
Labeling of adenovirus particles with PARACEST agents. Bioconjug Chem (2008) 0.99
SWIFT-CEST: a new MRI method to overcome T₂ shortening caused by PARACEST contrast agents. Magn Reson Med (2011) 0.98
A lanthanide complex with dual biosensing properties: CEST (chemical exchange saturation transfer) and BIRDS (biosensor imaging of redundant deviation in shifts) with europium DOTA-tetraglycinate. NMR Biomed (2011) 0.97
A paramagnetic chemical exchange-based MRI probe metabolized by cathepsin D: design, synthesis and cellular uptake studies. Org Biomol Chem (2010) 0.95
In vivo detection of PARACEST agents with relaxation correction. Magn Reson Med (2010) 0.93
In vivo detection of MRI-PARACEST agents in mouse brain tumors at 9.4 T. Magn Reson Med (2011) 0.89
Fluorescent and lanthanide labeling for ligand screens, assays, and imaging. Methods Mol Biol (2011) 0.89
MR imaging in cerebral gliomas analysis of tumour tissue components. Acta Radiol Suppl (1993) 0.88
The hope and hype of multimodality imaging contrast agents. Nanomedicine (Lond) (2011) 0.87
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology (2003) 3.71
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol (2008) 3.50
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res (2006) 2.56
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res (2008) 2.22
Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening. Magn Reson Med (2003) 2.20
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol (2004) 2.03
The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer (2009) 1.98
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies. Acc Chem Res (2009) 1.95
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Design and characterization of a new irreversible responsive PARACEST MRI contrast agent that detects nitric oxide. Magn Reson Med (2007) 1.88
An overview of responsive MRI contrast agents for molecular imaging. Front Biosci (2008) 1.83
Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol (2004) 1.82
MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology (2013) 1.77
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.70
MRI detects white matter reorganization after neural progenitor cell treatment of stroke. Neuroimage (2006) 1.69
PARACEST MRI with improved temporal resolution. Magn Reson Med (2009) 1.69
MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget (2013) 1.64
Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates. PLoS One (2013) 1.62
Enzyme-responsive PARACEST MRI contrast agents: a new biomedical imaging approach for studies of the proteasome. Contrast Media Mol Imaging (2007) 1.58
Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed (2006) 1.58
Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen (2006) 1.58
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol (2009) 1.54
Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging. Nat Med (2012) 1.53
Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther (2007) 1.53
Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report. J Neurooncol (2009) 1.52
Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab (2006) 1.51
Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI. Magn Reson Med (2013) 1.48
Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery (2002) 1.45
A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol (2012) 1.44
Effects of administration route on migration and distribution of neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study. J Cereb Blood Flow Metab (2009) 1.43
Quantification of superparamagnetic iron oxide (SPIO)-labeled cells using MRI. J Magn Reson Imaging (2007) 1.42
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol (2009) 1.41
Investigation of neural progenitor cell induced angiogenesis after embolic stroke in rat using MRI. Neuroimage (2005) 1.41
In vitro model of bromodeoxyuridine or iron oxide nanoparticle uptake by activated macrophages from labeled stem cells: implications for cellular therapy. Stem Cells (2008) 1.41
Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology (2012) 1.41
Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J (2008) 1.36
Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Mol Pharm (2009) 1.35
Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. Cancer Res (2013) 1.35
Imaging in vivo extracellular pH with a single paramagnetic chemical exchange saturation transfer magnetic resonance imaging contrast agent. Mol Imaging (2012) 1.34
Measuring in vivo tumor pHe with CEST-FISP MRI. Magn Reson Med (2011) 1.33
Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells (2010) 1.29
A self-calibrating PARACEST MRI contrast agent that detects esterase enzyme activity. Contrast Media Mol Imaging (2010) 1.29
AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma. Glia (2006) 1.29
Improved pH measurements with a single PARACEST MRI contrast agent. Contrast Media Mol Imaging (2012) 1.28
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol (2010) 1.26
Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One (2010) 1.24
Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J Cereb Blood Flow Metab (2008) 1.24
Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology (2014) 1.23
Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget (2013) 1.22
Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery (2004) 1.22
Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol (2009) 1.21
Angiogenesis detected after embolic stroke in rat brain using magnetic resonance T2*WI. Stroke (2008) 1.21
FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia (2008) 1.21
Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res (2006) 1.19
MRI identification of white matter reorganization enhanced by erythropoietin treatment in a rat model of focal ischemia. Stroke (2009) 1.19
Optimization and validation of FePro cell labeling method. PLoS One (2009) 1.19
9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N'-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. J Pharmacol Exp Ther (2005) 1.19
Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging. J Neurooncol (2010) 1.19
Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage. Stroke (2009) 1.18
GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis. Neuro Oncol (2008) 1.17
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol (2005) 1.16
The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum (2007) 1.16
MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One (2013) 1.15
Cerebral myogenic reactivity and blood flow in type 2 diabetic rats: role of peroxynitrite in hypoxia-mediated loss of myogenic tone. J Pharmacol Exp Ther (2012) 1.15
Quantitation and localization of blood-to-brain influx by magnetic resonance imaging and quantitative autoradiography in a model of transient focal ischemia. Magn Reson Med (2005) 1.15
Identification of variations in blood-brain barrier opening after cerebral ischemia by dual contrast-enhanced magnetic resonance imaging and T 1sat measurements. Stroke (2008) 1.15
Measurement of quantity of iron in magnetically labeled cells: comparison among different UV/VIS spectrometric methods. Biotechniques (2007) 1.15
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging (2004) 1.14
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.13
Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. Neuro Oncol (2006) 1.13
In Vivo Cellular Imaging for Translational Medical Research. Curr Med Imaging Rev (2009) 1.12
Acute leakage patterns of fluorescent plasma flow markers after transient focal cerebral ischemia suggest large openings in blood-brain barrier. Microcirculation (2008) 1.12
The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol (2009) 1.11